Latest Breaking News On - John schutte - Page 6 : comparemela.com

Press release content from Accesswire. The AP news staff was not involved in its creation. RepliCel Closes Second Tranche of Strategic Investment Commitment April 29, 2021 GMT MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the second tranche of the investment by MainPointe Pharmaceuticals (“MainPointe”) as outlined in the share purchase agreement signed earlier this year by the parties. This second tranche involved MainPointe’s purchase of 1,777,778 common shares issued by RepliCel in exchange for CAD $1,200,000 which has now been received by the Company.

United statesBritish columbiaJohn schutteLee bucklerReplicel life sciences incMainpointe pharmaceuticalsReplicel life sciencesDrug administrationChina health for greaterShiseido companyMainpointe pharmaceuticals completes largest scheduled shareRegulation services providerVenture exchangeUnited states securities actPointe pharmaceuticalsGreater china